Try
United Therapeutics Corporation
UTHRUnited States
41 filed reports · 478 financial concepts · 2 earnings calls · 6 media appearances
Filed reports
41 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 5,124 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 5,209 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 395 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 283 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 1,224 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 294 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 174 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 30, 2025 | 179 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 531 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 30, 2024 | 179 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Jul 31, 2024 | 174 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 1, 2024 | 174 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 21, 2024 | 495 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 1, 2023 | 155 | Open |
Financial data
478 concepts · 10,333 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial467 concepts · 8,696 facts · Dec 2014 to Jul 2026
- Due in one to three years92 · Dec 2017 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Aggregate STAP liability57 · Dec 2015 to Dec 2025
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Capital expenditures incurred but not yet paid56 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other operating capital net56 · Dec 2014 to Jun 2026
- Incremental common shares attributable to share based payment arrangements56 · Dec 2014 to Jun 2026
- Interest paid net56 · Dec 2014 to Jun 2026
- Nonoperating income expense56 · Dec 2014 to Jun 2026
- Other comprehensive income defined benefit plans adjustment net of tax portion attributable to parent56 · Dec 2014 to Jun 2026
- Other noncash income expense56 · Dec 2014 to Jun 2026
- Payments to acquire property plant and equipment56 · Dec 2014 to Jun 2026
- Proceeds from issuance of shares under incentive and share based compensation plans56 · Dec 2014 to Jun 2026
- Proceeds from stock options exercised56 · Dec 2014 to Jun 2026
Product9 concepts · 1,512 facts · Dec 2014 to Jun 2026
- Revenue712 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)321 · Dec 2016 to Jun 2026
- Gross profit (US GAAP)196 · Dec 2019 to Jun 2026
- Remodulin194 · Dec 2014 to Sep 2021
- Cost of goods sold71 · Dec 2014 to Dec 2017
- Adcirca7 · Dec 2017 to Dec 2021
- Orenitram5 · Sep 2015 to Mar 2016
- Inventory write down4 · Mar 2025 to Jun 2026
- Inventory firm purchase commitment loss2 · Mar 2026 to Jun 2026
Geography2 concepts · 125 facts · Dec 2014 to Jun 2026
- Revenue112 · Dec 2014 to Jun 2026
- Property, Plant & Equipment, Net13 · Dec 2015 to Dec 2021
Segments
1,637 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis9 members · 1,162 facts
- Adcirca173 · Dec 2017 to Jun 2026
- Orenitram169 · Dec 2017 to Jun 2026
- Remodulin169 · Dec 2017 to Jun 2026
- Unituxin169 · Dec 2017 to Jun 2026
- Tyvaso139 · Dec 2017 to Jun 2026
- Product And Service Other114 · Dec 2020 to Jun 2026
- Tyvaso DPI107 · Dec 2021 to Jun 2026
- Nebulized Tyvaso101 · Dec 2021 to Jun 2026
- Product21 · Dec 2017 to Sep 2022
Product or serviceus-gaap:ProductOrServiceAxis6 members · 350 facts
- Adcirca72 · Dec 2014 to Mar 2019
- Remodulin70 · Dec 2014 to Mar 2019
- Orenitram69 · Dec 2014 to Mar 2019
- Tyvaso69 · Dec 2014 to Mar 2019
- Unituxin65 · Jun 2015 to Mar 2019
- Product5 · Dec 2016 to Mar 2019
Statement geographicalsrt:StatementGeographicalAxis2 members · 84 facts
- Non Us42 · Dec 2017 to Jun 2026
- US42 · Dec 2017 to Jun 2026
Statement geographicalus-gaap:StatementGeographicalAxis4 members · 41 facts
- Non Us14 · Dec 2014 to Mar 2019
- US14 · Dec 2014 to Mar 2019
- Us7 · Dec 2015 to Dec 2021
- Non us6 · Dec 2015 to Dec 2021
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary123 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary197 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes7 claims from 1 reports · Dec 2025
- Risk factors66 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 6, 2026
Executive media
6 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances3 · Sep 2023 to Apr 2025
- TV interviews2 · May 2021 to Nov 2022
- Podcasts1 · May 2026
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.